Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Usana Health SciencesUSNA -2.86%66 ROC (Joel Greenblatt) % is 54.80% as of Mar. 2026, which is 61% below its 10-year median of 139.43. GuruFocus rates USNA with a GF Score™ of 66/100 and a GF Value™ of $41.41 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 1,979 Consumer Packaged Goods companies, Usana Health Sciences ranks better than 86.05% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Usana Health Sciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 54.80%.
The historical rank and industry rank for Usana Health Sciences's ROC (Joel Greenblatt) % or its related term are showing as below:
USNA'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 39.63 Med: 139.43 Max: 196.59
Current: 39.63
During the past 13 years, Usana Health Sciences's highest ROC (Joel Greenblatt) % was 196.59%. The lowest was 39.63%. And the median was 139.43%.
USNA's ROC (Joel Greenblatt) % is ranked better than 86.05% of 1979
companies
in the Consumer Packaged Goods industry
Industry Median: 11.99
vs USNA: 39.63
Usana Health Sciences's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -24.10% per year.
Usana Health Sciences (NYSE:USNA) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Usana Health Sciences ROC (Joel Greenblatt) % Related Terms
Usana Health Sciences ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Usana Health Sciences's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Usana Health Sciences ROC (Joel Greenblatt) % Chart
USNA vs NATR, ENHA, BYND: ROC (Joel Greenblatt) % Comparison
For the Packaged Foods subindustry, Usana Health Sciences's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Usana Health Sciences ROC (Joel Greenblatt) % vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Usana Health Sciences's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Usana Health Sciences's ROC (Joel Greenblatt) % falls into.
Usana Health Sciences ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 54.80% mean?
Usana Health Sciences (USNA) has a ROC (Joel Greenblatt) % of 54.80% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Usana Health Sciences and its competitors. This is 61% below median its historical median of 139.43. Over the past decade, Usana Health Sciences' ROC (Joel Greenblatt) % has ranged from 39.63 to 196.59. According to the industry distribution chart, Usana Health Sciences ranks #276 out of 1979 companies in the Consumer Packaged Goods industry, placing it in the top 13.9%.
Is Usana Health Sciences' ROC (Joel Greenblatt) % too high?
Usana Health Sciences' current ROC (Joel Greenblatt) % of 54.80% is 61% below median its 10-year median of 139.43. Over the past 10 years, this metric has ranged from a low of 39.63 to a high of 196.59. The Consumer Packaged Goods industry median ROC (Joel Greenblatt) % is 11.99. Usana Health Sciences' value of 54.80% is 357% above this industry median. Based on the distribution chart, Usana Health Sciences ranks #276 out of 1979 companies in the Consumer Packaged Goods industry, which is in the top quartile — a strong position relative to peers. Overall, Usana Health Sciences has a GF Score™ of 66/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Usana Health Sciences' ROC (Joel Greenblatt) % compare to NATR and ENHA?
According to the Consumer Packaged Goods industry distribution chart, Usana Health Sciences ranks #276 out of 1979 companies for ROC (Joel Greenblatt) %. This places Usana Health Sciences in the top 14% of its industry — outperforming the majority of peers. The industry median ROC (Joel Greenblatt) % is 11.99. Usana Health Sciences' value of 54.80% is 357% above this benchmark. Historically, Usana Health Sciences' own ROC (Joel Greenblatt) % has ranged from 39.63 to 196.59 over the past decade. While the company's 10-year median is 139.43 vs. the industry median of 11.99, Usana Health Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Consumer Packaged Goods company?
The median ROC (Joel Greenblatt) % among Consumer Packaged Goods companies is 11.99, based on 1,979 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Usana Health Sciences's current ROC (Joel Greenblatt) % of 54.80% is 357% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Usana Health Sciences and its competitors. For the Consumer Packaged Goods industry, the median ROC (Joel Greenblatt) % is 11.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Usana Health Sciences's current ROC (Joel Greenblatt) % is 54.80%, which is 61% below median its own 10-year median of 139.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Usana Health Sciences stock overvalued right now?
Based on GuruFocus' analysis, Usana Health Sciences (USNA) is currently considered Possible Value Trap. The stock's GF Value™ is $41.41, compared to a current price of $21.40 — trading 48.3% below its estimated fair value. The current ROC (Joel Greenblatt) % is 54.80%, which is 61% below median its 10-year median of 139.43 and 357% above the Consumer Packaged Goods industry median of 11.99. Usana Health Sciences' overall GF Score™ is 66/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Usana Health Sciences (USNA), the current ROC (Joel Greenblatt) % is 54.80% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Usana Health Sciences (USNA) Overvalued in 2026?
Based on GuruFocus' analysis, Usana Health Sciences stock appears to be undervalued.
The current stock price of $21.40 is trading 48.3% below its estimated GF Value™ of $41.41.
GuruFocus considers Usana Health Sciences to be Possible Value Trap.
Key valuation signals for USNA:
ROC (Joel Greenblatt) %: 54.80% (61% below median its 10-year median of 139.43)
GF Value™: $41.41 vs. price of $21.40 (48.3% below fair value)
Industry Position: 357% above the Consumer Packaged Goods median (#276 of 1979)
No single metric tells the full story. See the USNA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Usana Health Sciences Inc develops and manufactures high-quality nutritional supplements, functional foods, and personal care products that are sold throughout the world. The company has developed and manufactured high-quality, science-based nutritional, personal care, and skincare products with a primary focus on promoting long-term health and wellness. The Company's reporting units for goodwill purposes are tied to its reportable segments: Core nutritional and Hiya direct-to-consumer. The core nutritional segment consists of three individual reporting units that are determined based on the operational nature of the business: Buy-Sell, China, and India. Geographically, it is in Asia Pacific, the Americas, and Europe. With the majority of revenue from Asia Pacific(Greater China).
66GF Score
Get the complete analysis for USNA
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
USNA has been successfully added to your 
